Bio-Techne
614 McKinley Place N.E.
Minneapolis
Minnesota
55413
United States
Website: http://www.bio-techne.com/
405 articles about Bio-Techne
-
BIO-TECHNE LAUNCHES THE MauriceFlex™ SYSTEM, ADDING cIEF FRACTIONATION CAPABILITY TO THE GOLD STANDARD MAURICE ASSAYS
1/26/2023
Bio-Techne Corporation (NASDAQ: TECH) today announced the launch of its ProteinSimple-branded MauriceFlex™ during the WCBP conference in Washington D.C. MauriceFlex™ enables protein charge variant fractionation plus routine cIEF & a CE-SDS assays.
-
BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 2, 2023, TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS
1/17/2023
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Thursday, February 2, 2023 , at 8:00 a.m. CST to review second quarter 2023 financial results.
-
BIO-TECHNE LAUNCHES RNASCOPE PLUS ASSAY TO ADVANCE GENE THERAPY DEVELOPMENT
1/10/2023
Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of its Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of the RNAscope Plus smRNA-RNA detection assay.
-
BIO-TECHNE TO PRESENT AT THE 41st ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
12/21/2022
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 , at 8:15 a.m. PST.
-
BIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS
12/5/2022
Bio-Techne Corporation (NASDAQ: TECH) today announced the introduction of MitoBrilliant ™ probes.
-
BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE
11/28/2022
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth , President and Chief Executive Officer, will present at the Fifth Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022 , at 8:50 a.m. EST.
-
NAMOCELL HIGHLIGHTED IN NATURE PUBLICATION FOR EFFICIENT SINGLE CELL CLONING OF HUMAN PLURIPOTENT STEM CELLS
11/17/2022
Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell ™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and trans-ISRIB (CEPT) cocktail.
-
Bio-Techne Announces Opening of New Immunoassay Manufacturing Facility
11/15/2022
Bio-Techne Corporation announced the opening of its new 52,000 square foot state-of-the-art product innovation and manufacturing facility.
-
Bio-Techne to Present at the Stephens Annual Investment Conference
11/10/2022
Bio-Techne Corporation announced that Jim Hippel, Executive Vice President and Chief Financial Officer, will present at the Stephens Annual Investment Conference on Thursday, November 17, 2022, at 10:00 a.m. CST.
-
BIO-TECHNE TO PRESENT AT THE STIFEL 2022 HEALTHCARE CONFERENCE
11/8/2022
Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 , at 2:25 p.m. EST.
-
Bio-Techne to Present at the Credit Suisse 31st Annual Healthcare Conference
11/3/2022
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Credit Suisse 31st Annual Healthcare Conference on Wednesday, November 9, 2022, at 8:35 a.m. PST.
-
Bio-Techne Releases First Quarter Fiscal 2023 Results
11/1/2022
Bio-Techne Corporation reported its financial results for the first quarter ended September 30, 2022.
-
Bio-Techne Declares Cash Dividend and Stock Dividend payable November 28, 2022
11/1/2022
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2022.
-
Asuragen to Showcase Innovative Diagnostic Lab Solutions at AMP 2022 Conference
10/31/2022
Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, will present its diagnostic lab solutions at the upcoming annual meeting of the Association for Molecular Pathology (AMP), taking place November 1-5 in Phoenix, Ariz.
-
Bio-Techne Introduces New Simple Plex AAV Viral Titer Assays
10/11/2022
Bio-Techne Corporation and PROGEN announced the release of three new Simple Plex™ Adeno-Associated Virus viral titer assays for intact AAV capsid quantification.
-
BIO-TECHNE TO HOST CONFERENCE CALL ON NOVEMBER 1, 2022, TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS
10/10/2022
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 1, 2022 , at 8:00 a.m. CDT to review first quarter 2023 financial results.
-
BIO-TECHNE COMMERCIALIZES AUTOMATED MULTI-OMIC RNASCOPE ASSAYS FOR SPATIAL VISUALIZATION OF RNA AND PROTEIN BIOMARKERS IN FFPE TISSUES
10/6/2022
Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of the Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of new automated co-detection assays specifically designed for the Roche DISCOVERY ULTRA Platform, enabling simultaneous detection of RNA and protein on the same tissue section.
-
ScaleReady Introduces the Cue® Cell Processing System From Fresenius Kabi
10/3/2022
ScaleReady Introduces the Cue ® Cell Processing System From Fresenius Kabi.
-
Bio-Techne Files Patent Infringement Lawsuit Against Molecular Instruments
9/26/2022
Bio-Techne Corporation today announced that it has taken legal action in the United Kingdom to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.
-
BIO-TECHNE ISSUES 2022 CORPORATE SUSTAINABILITY REPORT
9/19/2022
Bio-Techne Corporation (NASDAQ: TECH) today issued its 2022 Corporate Sustainability Report (CSR).